long intergenic non-protein coding RNA 2778Genealiases: []
Q-omics provides the consensus-scored LINC02778 profile across patient tissues and cancer cell-line models. LINC02778 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in TGCT. Among the 18 cancer types available for tumor–normal comparison, LINC02778 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, LINC02778 RNA expression shows 6,468 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight TGCT, KIRC, and STAD as cancer lineages where LINC02778 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02778 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02778 survival associations across molecular data types. LINC02778 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02778 RNA expression–survival associations across cancer types. High LINC02778 expression shows unfavorable associations in TGCT, LIHC, STAD, KIRP and ESCA, but favorable associations in BLCA. The TGCT Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify TGCT as the clearest survival context for LINC02778 RNA expression.
This table summarizes LINC02778 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02778. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02778 shows lower tumor expression in KIRC, KICH and KIRP. The KIRC box plot shows higher LINC02778 RNA expression in normal versus tumor tissue (log2 FC = −1.255, t-test p < 0.001).
This table shows molecular features associated with LINC02778 in patient tissues and cancer cell lines. In patient samples, LINC02778 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
